BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding ...
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
NORTHAMPTON, MA / ACCESSWIRE / November 11, 2024 / In 2018, T-Mobile unveiled an expansive, companywide initiative to hire 10,000 veterans and military spouses over a five-year time period. By the end ...
DETROIT — A jury awarded more than $12 million Friday to a woman who lost her job at a Michigan insurance company after declining to get a COVID-19 vaccination. Much of the award — $10 million — is ...
European markets are expected to start the week on a mostly positive note Monday, with all eyes on Tuesday's presidential ...
Ex-Google European Hypergrowth Leader Fabian Rucker Joins Blue Ridge Partners Management Consultancy
Global consultancy strengthens itsEuropean leadership team as part of ongoing growth strategy FRANKFURT, Germany, Oct. 29, 2024 /PRNewswire/ -- Blue Ridge Partners is pleased to announce the ...
About the BLUE-C Study BLUE-C was a multi-center, prospective study (NCT04144738) of more than 20,000 adults 40 years of age and older. The trial was designed to evaluate the performance of ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback